Stock CYCN CYCLERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Market Closed - Nasdaq
Other stock markets
 21:30:00 26/04/2024 BST 		5-day change 1st Jan Change
2.93 USD -3.62% Intraday chart for Cyclerion Therapeutics, Inc. -16.29% -12.54%
03-05 Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Cyclerion Therapeutics, Inc. Appoints Regina Graul as President CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Cyclerion Therapeutics to Sell Zagociguat, CY3018 Assets to New Private Company
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment
Cyclerion Therapeutics Says FDA Grants Orphan Drug Designation to Zagociguat; Shares Jump
Cyclerion Therapeutics' Zagociguat Gets FDA Orphan Drug Status
Cyclerion Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
A group including Cyclerion Therapeutics, Inc.'s Chief Executive Officer cancelled the acquisition of Certain Assets of Cyclerion Therapeutics, Inc..
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Cyclerion Therapeutics, Inc. Announces Resignation of Andreas Busch as Chief Scientific Officer
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Cyclerion Therapeutics, Inc. Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYCN Stock
  4. News Cyclerion Therapeutics, Inc.
  5. Other languages